Glenmark Pharmaceuticals announced that NSE Sustainability Ratings and Analytics Limited has independently assigned the company an ESG rating of “68” for the Financial Year 2025. The company clarified that it has not engaged NSE Sustainability for this assessment, as the rating was derived solely from publicly available information. This disclosure fulfills regulatory requirements under the applicable listing obligations.
ESG Rating Disclosure for FY 2025
Glenmark Pharmaceuticals Limited has issued a formal disclosure regarding its Environmental, Social, and Governance (ESG) performance evaluation for the Financial Year ending 2025. This communication was made public on February 20, 2026.
Rating Assignment Details
The firm was informed via email on February 20, 2026, that NSE Sustainability Ratings and Analytics Limited (NSE Sustainability) assigned a specific rating score. The assigned rating for F.Y. 2025 stands at “68”.
Clarification on Engagement
It is important to note that Glenmark Pharmaceuticals has not engaged NSE Sustainability directly for this evaluation. The assigned rating was determined independently by NSE Sustainability based strictly on information publicly available concerning the Company’s operations during F.Y. 2025. The management requested that this information be officially recorded by the stock exchanges.
Source: BSE
